CDK4 and medulloblastoma: In a high-throughput drug screen, BRD4 inhibitors have been found to be one of the two classes of compounds exerting the best synergistic anticancer effects with the CDK4/CDK6 inhibitor Ribociclib in medulloblastoma cells [47].